Skip to main content
GRI Bio, Inc. logo

GRI Bio, Inc. — Investor Relations & Filings

Ticker · GRI ISIN · US3622AW4030 US Manufacturing
Filings indexed 371 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US GRI

About GRI Bio, Inc.

https://www.gribio.com/

GRI Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapies for inflammatory, fibrotic, and autoimmune diseases. The company's primary focus is on advancing its pipeline of Natural Killer T (NKT) cell modulators. This therapeutic strategy targets the initial stages of the inflammatory cascade, aiming to interrupt disease progression and fundamentally alter the treatment of these conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
10-Q - GRI Bio, Inc. (0001824293) (Filer)
Interim / Quarterly Report
2026-05-13 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-10 English
8-K Filing
Regulatory Filings
2026-02-04 English
8-K - GRI BIO, INC. (0001824293) (Filer)
Regulatory Filings
2026-01-30 English
S-3 - GRI BIO, INC. (0001824293) (Filer)
Registration Form
2026-01-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.